Gorrissen Federspiel’s Life Sciences Strategic Licensing team has proudly assisted Camurus AB, a science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases, in a deal with Gubra, a company specialized in peptide-based drug discovery.
On 16 December, the parties announced an exclusive collaboration and license agreement aimed at creating a long-acting therapeutic option for the treatment of hypoparathyroidism.
This research and development program will combine Gubra’s parathyroid hormone (PTH) analogue, developed using its proprietary streaMLine peptide discovery platform, with Camurus’ FluidCrystal® technology to enable extended, patient-friendly dosing.
Under the agreement, Camurus will develop and commercialize the product and Gubra has the option to co-finance the product through development.
Gubra will receive tiered royalties scaled to its chosen level of financial participation.
The Gorrissen Federspiel core team consisted of Søren Høgh Thomsen and Martin Dræbye Gantzhorn.
Congratulations to both parties and all involved.